Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-108459 in Paroxysmal or Persistent Atrial Fibrillation
NCT02069119Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Feb 2014
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Atrial fibrillation (AFib) comparing OPC-108459 with Placebo (2 arms). Primary endpoints: Subjects Achieving Normal Sinus Rhythm (NSR) in Patients With Paroxysmal AF, Subjects Achieving Normal Sinus Rhythm (NSR) in Patients With Persistent AF and 2 more. Started Feb 2014; status: completed.
02
Drugs
OPC-108459
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02069119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02069119.